PRECISION MEDICINE SUMMIT: A HIMSS EVENT
BOSTON, MA - JUNE 12 - 13, 2017
Eric Dishman is the director of the All of Us Research Program at the National Institutes of Health. In this role, he leads efforts to build a research cohort of one million U.S. participants to advance precision medicine.
Previously, Dishman was an Intel fellow and vice president of the Health and Life Sciences Group at Intel Corporation, where he was responsible for driving Intel’s cross-business strategy, research and development, and product and policy initiatives for health and life science solutions.
He is widely recognized as a global leader in healthcare innovation with specific expertise in home and community-based technologies and services for chronic disease management and independent living. Trained as a social scientist, Dishman is known for pioneering innovation techniques that incorporate anthropology, ethnography, and other social science methods into the development of new technologies. He also brings his own experience as a cancer patient for 23 years—finally cured thanks to precision medicine—to drive a person-centric view of healthcare transformation.
Stephanie Devaney, deputy director, All of Us Research Program, National Institutes of Health, will provide an update of the implementation of the Precision Medicine Initiative (PMI), a federal, inter-agency effort to accelerate the research and development of personalized therapies for patients. She will also provide an update on the All of Us Research program, a historic research undertaking part of PMI, which will create a national, patient-powered cohort of one million or more Americans who will volunteer to participate in research throughout their lives and help unlock our understanding of diseases.
Despite amazing technological breakthroughs for precision medicine, government champions, and continuing and significant investment, challenges exist related to appropriate regulatory guidelines, suitable reimbursement, and the education of healthcare professionals.
In this kick-off leadership panel, our experts discuss the current state of precision medicine and how to overcome these challenges. Additionally, they’ll address how to realistically: